Non-small cell lung cancer (NSCLC)
FURMO-006
A Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Osimertinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Mutations.
Trial overview
Clinical Area
Medical Oncology
Disease
Non-small cell lung cancer (NSCLC)
Disease site
Lung & bronchus
Study Phase
III
Trial Identifiers
Registration number: NCT07185997
GenesisCare Location(s)
Principal Investigator(s)